Three-quarters of CAC2 member organizations fund essential research projects related to childhood and AYA cancer.  The coverage is deep and broad:  across the spectrum of development, from basic research through to clinical trials; across a wide range of topics, including data sharing, crucial medicines, psycho-social standards, and survivorship; and across the country and around the world.

Research funded by our members is crucial to discovering more effective treatments that minimize side effects and increase quality of life during and after treatment.  Most importantly, that research investment represents a shared aim to find cures for all types of childhood cancer.  CAC2 celebrates each and every member’s efforts to help close the large and persistent gap between funding needs to achieve this goal andavailable resources.

CAC2 doesn’t just applaud our member’s individual efforts but strives to act as a catalyst for research members to work collaboratively to effect positive change in the childhood cancer research community.  The Research and Treatment Interest Group has a four-pronged strategy for achieving this goal.

  • Hosting educational conferences and webinars across a multi-disciplinary childhood cancer research audience to encourage exchange of information and build relationships
  • Providing information to respective members regarding co-funding research projects opportunities typically sourced by a member organization in need of additional funding
  • Developing online repositories for childhood cancer research progress including:
    • Founding of the Childhood Cancer Fact Library to assist CAC2 member organizations with current data and information related to progress in the childhood cancer arena
    • Launching the childhood cancer research project database with the International Cancer Research Partnership, a global source of cancer research projects, to help foster cooperation and strategic coordination between childhood cancer organizations
  • Establishing the Ethics Think Tank Working Group to help identify best practices and potential ethical issues associated with pediatric cancer charities that fund researchers and the relationships between those organizations and the research recipients.

The Research and Treatment interest Group strives to establish CAC2 as a credible resource for moving the field of pediatric cancer forward through thoughtful, progressive studies and projects.

ALL member organizations with a research interest or focus are encouraged to participate in the work of the CAC2 Research and Treatment Interest Group. Volunteers are welcome to join a committee on a rolling basis. Please contact us at  for more information.

“Talent wins games, but teamwork and intelligence win championships.” – Michael Jordan

ICRP Database
Research News
CAC2 Research Conference Proceedings

Latest CAC2 and Community News

CAC2 Webinar–Hearing Loss from Cisplatin—Multiple Perspectives on the New FDA Preventative Treatment Option

Children who receive cisplatin as part of their cancer treatment are at risk for progressive and/or permanent hearing loss as a result of their treatment.  This treatment effect can influence speech and language development, educational achievement, and social-emotional development.  Recently, ...
Read More

CAC2 Childhood Cancer Community News Digest (November 21-27)

Assorted News from the Last Week: CAC2 Member Mary Beth Collins explains the importance of the new FDA approval of Pedmark:  "With the FDA’s recent approval of Pedmark (an injectable formulation of sodium thiosulfate ("STS"), children are protected from cisplatin’s ototoxicity.  This ...
Read More

CAC2 Childhood Cancer Community News Digest (November 14-20)

Assorted News from the Last Week: CAC2 Member Joe Baber reflects on the Gabriella Miller Kids First 2.0 legislation pending in Congress:  "We’re all thankful when there are lifesaving therapies and at the very same time, we are fearful of ...
Read More